Skip to main content

Week in Review: China Biopharma Books $500 Million of Deals to Start 2022

Deals and Financings   Shanghai AffaMed acquired greater  China  rights to an ophthalmic drug from Korea 's Hanmi Pharma in an $145 million agreement; Sperogenix Therapeutics of  Beijing in-licensed China rights to a rare disease drug from  Switzerland 's Santhera in a deal valued at up to $124 million; Xuanzhu Biopharm, a subsidiary of Sihuan Pharm, completed a $96 million Series B financing to develop novel drugs for  China ; Accro Bioscience ( Suzhou ) raised more than $50 million in an oversubscribed Series B round to develop regulated cell death products; Jiangsu Atom Bioscience closed a $45 million Series C financing to support a global Phase III clinical trial of a treatment for gout; Shanghai Nuance Pharma acquired Sino Health Pharmaceutical together with two of its subsidiaries in a deal worth at least $32 million; Shanghai Junshi Bio formed a collaboration with  Singapore 's DotBio to discover next-gen antibody therapies using a DotBody module;  Company News   Chengdu Clover Biopharma started construction of a Shanghai R&D Center  to develop novel vaccines and biologic therapies;  Trials and Approvals   Akeso, a  Hangzhou  biopharma, was approved to start a China Phase Ib/II trial of a dual PD-1-based bi-specific therapy for NSCLC; Suzhou CStone Pharma was approved to start a US Phase I trial of an ADC targeting receptor tyrosine kinase-like orphan receptor 1.  Stock Symbols: (HK: 0460) (HK: 1877: SHA: 688180) (HK: 02197) (HK: 09926) (HK: 2616) Share this with colleagues: // //
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.